Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ALPMF - FDA OKs Seattle Genetics ADC for urothelial cancer; shares up 6% after hours


ALPMF - FDA OKs Seattle Genetics ADC for urothelial cancer; shares up 6% after hours

  • Under accelerated review status, the FDA approves Seattle Genetics (NASDAQ:SGEN) and collaboration partners Astellas Pharma's (OTCPK:ALPMF) antibody-drug conjugate (ADC) Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and platinum-containing chemo before (neoadjuvant) or after (adjuvant) surgery.
  • More news on: Seattle Genetics, Inc., Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks news, Stocks on the move,
  • Read more ...
Stock Information

Company Name: Astellas Pharma Inc
Stock Symbol: ALPMF
Market: OTC

Menu

ALPMF ALPMF Quote ALPMF Short ALPMF News ALPMF Articles ALPMF Message Board
Get ALPMF Alerts

News, Short Squeeze, Breakout and More Instantly...